Hormone Replacement Therapy Market size is poised to expand from USD 37.29 billion to USD 98.63 billion, reflecting a CAGR of more than 7.7% throughout the forecast period, from 2025 to 2037. In the year 2025, the industry size of hormone replacement therapy is evaluated at USD 39.62 billion.
The market growth is attributed to higher prevalence of chronic conditions such as hypogonadism in adult males across the globe. For instance, globally, hypogonadal males account for approximately 42% of men over the age of 45 and 55% of men in their 80s. Moreover, rising awareness regarding the post- menopausal issues among women is another factor driving the market revenue.
Skyrocketing investment by the government in the R&D of new medical technology and the growing prevalence of high blood pressure & hypertension are anticipated to boost the market revenue. For instance, it is estimated that in every 4 adults, 1 of them aged between 20 to 45 suffers from high blood pressure worldwide. Additionally, in 2018, around 45% of the global population was projected to live with hypertension.
Growth Drivers
Challenges
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
7.7% |
Base Year Market Size (2024) |
USD 37.29 billion |
Forecast Year Market Size (2037) |
USD 98.63 billion |
Regional Scope |
|
Administration Route (Parenteral, Transdermal, Oral)
The transdermal segment in the hormone replacement therapy market is set to witness lucrative growth till 2037. The growth of the segment is due to rising demand for transdermal drug delivery and ease of application. For instance, it is estimated that over 1 million transdermal patches are produced worldwide every year.
Our in-depth analysis of the global market includes the following segments:
By Replacement Therapy |
|
By Administration Route |
|
By Indication |
|
North America Market Forecast
North America hormone replacement therapy market is estimated to dominate largest revenue share by 2037. The market expansion can be ascribed to growth in the geriatric population along with presence of a well-structured healthcare infrastructure. World Bank released a set of data showing the geriatric population in the United States reached 56,545,938 in 2021. Moreover, rising cases of cancer and spiking penetration of major key players of the market in the region are expected to hike the market growth.
Orion Pharma AB to acquire the clearance for darolutamide indication in the combination with docetaxel from U.S. Food and Drug Administration (FDA). The product is developed for the treatment of metastatic hormone-sensitive prostate cancer shortly known as (mHSPC).
Genentech, Inc. to release positive results from the Phase III SKYSCRAPER-01 study. The study was being conducted to monitor the anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) vs Tecentriq alone as an initial (first-line) to find the cure for people living with advanced or metastatic non-small cell lung cancer (NSCLC).
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?